Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$51.95

-0.54 (-1.03%)

, BMY

Bristol-Myers

$54.66

0.74 (1.37%)

09:06
10/04/16
10/04
09:06
10/04/16
09:06

Five Prime advances into Phase 1b portion of combination trial

Five Prime Therapeutics (FPRX) announced that it has initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab, Five Prime's investigational monoclonal antibody that inhibits colony stimulating factor-1 receptor, with OPDIVO, Bristol-Myers Squibb's (BMY) PD-1 immune checkpoint inhibitor, in multiple tumor types. Five Prime initiated the Phase 1a/1b trial, which is expected to enroll approximately 280 patients, in September 2015. During Phase 1a, Five Prime evaluated the safety, pharmacokinetics and biomarkers of escalating doses of cabiralizumab as a monotherapy, as well as in combination with the approved 3 mg/kg dose of nivolumab. Five Prime will continue to run the Phase 1b portion of the trial and will evaluate the safety, tolerability and preliminary efficacy of the selected dose of cabiralizumab in combination with nivolumab for the treatment of advanced solid tumors, including but not limited to non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer.

FPRX

Five Prime

$51.95

-0.54 (-1.03%)

BMY

Bristol-Myers

$54.66

0.74 (1.37%)

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

FPRX Five Prime
$51.95

-0.54 (-1.03%)

01/20/16
FBCO
01/20/16
INITIATION
Target $54
FBCO
Outperform
Five Prime initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kennen MacKay started Five Prime Therapeutics with an Outperform rating and $54 price target.
01/21/16
01/21/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M (MMM) initiated with a Buy at Citi... AMAG Pharmaceuticals (AMAG) initiated with an Equal Weight at Barclays... Acceleron (XLRN) initiated with an Outperform at Credit Suisse... Agios Pharmaceuticals (AGIO) initiated with an Outperform at Credit Suisse... Akebia (AKBA) initiated with a Neutral at Credit Suisse... CIT Group (CIT) initiated with a Hold at Deutsche Bank... Check Point (CHKP) initiated with a Neutral at Cleveland Research... Clovis (CLVS) initiated with an Outperform at Credit Suisse... Colfax (CFX) initiated with a Sell at Citi... Danaher (DHR) initiated with a Neutral at Citi... Dover (DOV) initiated with a Neutral at Citi... Emerson (EMR) initiated with a Sell at Citi... Endo (ENDP) initiated with an Equal Weight at Barclays... Endocyte (ECYT) initiated with an Outperform at Credit Suisse... FibroGen (FGEN) initiated with a Neutral at Credit Suisse... FireEye (FEYE) initiated with an Outperform at Northland... Five Prime (FPRX) initiated with an Outperform at Credit Suisse... Flowserve (FLS) initiated with a Neutral at Citi... General Electric (GE) initiated with a Buy at Citi... Honeywell (HON) initiated with a Buy at Citi... Ignyta (RXDX) initiated with an Outperform at Credit Suisse... Illinois Tool Works (ITW) initiated with a Buy at Citi... Imperva (IMPV) initiated with an Outperform at Northland... Ingersoll-Rand (IR) initiated with a Buy at Citi... Joint Corp. (JYNT) initiated with a Buy at Maxim... M&T Bank (MTB) resumed with a Neutral at JPMorgan... Medivation (MDVN) initiated with an Outperform at Credit Suisse... Newfield Exploration (NFX) initiated with an Outperform at Imperial Capital... OvaScience (OVAS) initiated with an Underperform at Credit Suisse... PFSweb (PFSW) initiated with a Buy at Canaccord... Palo Alto (PANW) initiated with an Outperform at Northland... Perrigo (PRGO) initiated with an Overweight at Barclays... Prothena (PRTA) initiated with an Outperform at Credit Suisse... Puma Biotechnology (PBYI) initiated with an Outperform at Credit Suisse... Rockwell Automation (ROK) initiated with a Neutral at Citi... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... Shopify (SHOP) initiated with an Outperform at Wedbush... Square (SQ) initiated with a Market Perform at William Blair... TESARO (TSRO) initiated with an Outperform at Wedbush... Tyco (TYC) initiated with a Neutral at Citi... Ultragenyx (RARE) initiated with an Outperform at Credit Suisse.
05/11/16
05/11/16
NO CHANGE

Leerink major pharma & biotech analyst holds analyst/industry conference call
Biotech Analyst Schmidt and Major Pharmaceuticals Analyst Fernandez, along with University of Chicago Departments of Pathology & Medicine, Professor Dr. Thomas F. Gajewski, discuss the tumor micro-environment on an Analyst/Industry conference call to be held on May 11 at 2 pm.
08/09/16
WELS
08/09/16
NO CHANGE
WELS
Five Prime weakness overdone, says Wells Fargo
After a trial of the OPDIVO cancer treatment of Five Prime's (FPRX) partner, Bristol Myers Squibb (BMY), showed disappointing results, Wells Fargo thinks that the nearly 9% decline in Five Prime's stock was overdone. The firm thinks that it's "premature" to determine that Merck's (MRK) Keytruda has overtaken OPDIVO. The firm believes that Five Prime's OPDIVO can redeem itself in upcoming studies, and it thinks that Five Prime's stock can advance if the actor-1 receptor is proven to be a worthwhile target ,whether or not OPDIVO is shown to be effective. The firm keeps an Outperform rating on Five Prime.
BMY Bristol-Myers
$54.66

0.74 (1.37%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

02:30
01/16/18
01/16
02:30
01/16/18
02:30
General news
FX Update: The dollar has settled above yesterday's trend lows »

FX Update: The dollar has…

01:45
01/16/18
01/16
01:45
01/16/18
01:45
General news
FX Action: USD-JPY has lifted to the upper 110.0s »

FX Action: USD-JPY has…

F

Ford

$13.23

0.07 (0.53%)

, FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

20:06
01/15/18
01/15
20:06
01/15/18
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

F

Ford

$13.23

0.07 (0.53%)

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

TSLA

Tesla

$336.22

-1.73 (-0.51%)

BMWYY

BMW

$36.52

0.835 (2.34%)

TM

Toyota

$137.20

0.29 (0.21%)

GM

General Motors

$44.07

-0.12 (-0.27%)

VLKAY

Volkswagen

$44.34

1.065 (2.46%)

FB

Facebook

$179.37

-8.4 (-4.47%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

AAPL

Apple

$177.09

1.81 (1.03%)

NFLX

Netflix

$221.23

3.99 (1.84%)

VIVHY

Vivendi

$28.42

-1.035 (-3.51%)

BEN

Franklin Resources

$44.53

0.59 (1.34%)

PFE

Pfizer

$36.54

-0.02 (-0.05%)

AMGN

Amgen

$185.04

3.08 (1.69%)

ABBV

AbbVie

$100.34

1.07 (1.08%)

LLY

Eli Lilly

$86.98

0.59 (0.68%)

BMY

Bristol-Myers

$62.81

0.34 (0.54%)

JNJ

Johnson & Johnson

$145.76

0.97 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 03

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 05

    Mar

  • 18

    Mar

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

AAPL

Apple

$177.09

1.81 (1.03%)

19:29
01/15/18
01/15
19:29
01/15/18
19:29
Periodicals
China consumer group seeking answers from Apple on slowing iPhones, Reuters says »

A Chinese consumer group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

TWX

Time Warner

$92.05

0.16 (0.17%)

, CMCSA

Comcast

$42.44

-0.16 (-0.38%)

18:52
01/15/18
01/15
18:52
01/15/18
18:52
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend again »

Sony's (SNE)…

TWX

Time Warner

$92.05

0.16 (0.17%)

CMCSA

Comcast

$42.44

-0.16 (-0.38%)

CMCSK

Comcast

SNE

Sony

$50.03

-0.25 (-0.50%)

FOX

21st Century Fox

$36.37

0.57 (1.59%)

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

LGF.A

Lionsgate

$33.71

0.43 (1.29%)

DIS

Disney

$112.47

1.48 (1.33%)

VIAB

Viacom

$33.76

2.95 (9.57%)

VIA

Viacom

$39.10

3.45 (9.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

FNSR

Finisar

$22.74

0.48 (2.16%)

18:41
01/15/18
01/15
18:41
01/15/18
18:41
Downgrade
Finisar rating change at Goldman Sachs »

Finisar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

18:41
01/15/18
01/15
18:41
01/15/18
18:41
Upgrade
Adtran rating change at Goldman Sachs »

Adtran upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

CIEN

Ciena

$21.94

0.06 (0.27%)

18:40
01/15/18
01/15
18:40
01/15/18
18:40
Upgrade
Ciena rating change at Goldman Sachs »

Ciena upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

18:36
01/15/18
01/15
18:36
01/15/18
18:36
Periodicals
Auto1 says no need for IPO following SoftBank investment, Reuters reports »

Auto1 said a $561M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$22.07

0.33 (1.52%)

18:32
01/15/18
01/15
18:32
01/15/18
18:32
Hot Stocks
FDA approves Teva's Trisenox injection for Acute Promyelocytic Leukemia »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

, GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

18:26
01/15/18
01/15
18:26
01/15/18
18:26
Periodicals
Google relaunching map service in China, Nikkei reports »

Google has relaunched its…

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 18

    Mar

AAPL

Apple

$177.09

1.81 (1.03%)

, TCEHY

Tencent

$56.92

1.565 (2.83%)

18:24
01/15/18
01/15
18:24
01/15/18
18:24
Periodicals
Apple, Tencent reach deal to allow WeChat users dole out tips, WSJ says »

Apple (AAPL) and Tencent…

AAPL

Apple

$177.09

1.81 (1.03%)

TCEHY

Tencent

$56.92

1.565 (2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

RDS.A

Royal Dutch Shell

$70.88

1.04 (1.49%)

, RDS.B

Royal Dutch Shell

$72.70

0.97 (1.35%)

18:20
01/15/18
01/15
18:20
01/15/18
18:20
Periodicals
Shell acquires stake in solar energy company, Axios reports »

Royal Dutch Shell has…

RDS.A

Royal Dutch Shell

$70.88

1.04 (1.49%)

RDS.B

Royal Dutch Shell

$72.70

0.97 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

18:17
01/15/18
01/15
18:17
01/15/18
18:17
Periodicals
Citi to raise pay for women, minorities, Reuters reports »

Citigroup will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

18:10
01/15/18
01/15
18:10
01/15/18
18:10
Periodicals
Fiat Chrysler CEO rules out selling Jeep business, splitting up, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$8.08

0.13 (1.64%)

18:06
01/15/18
01/15
18:06
01/15/18
18:06
Hot Stocks
SSR Mining reports production of over 370,000 gold equivalent ounces in 2017 »

SSR Mining said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$87.52

0.59 (0.68%)

17:57
01/15/18
01/15
17:57
01/15/18
17:57
Hot Stocks
Exxon Mobil encounters hydrocarbons onshore Papua New Guinea »

ExxonMobil announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEF

Central Fund of Canada Ltd

$13.68

0.23 (1.71%)

17:56
01/15/18
01/15
17:56
01/15/18
17:56
Hot Stocks
Central Fund of Canada Ltd, Sprott announce plan of arrangement closing date »

Central Fund of Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$39.45

-0.1 (-0.25%)

17:52
01/15/18
01/15
17:52
01/15/18
17:52
Hot Stocks
Adelphia files application for certificate of public convenience and necessity »

Following the conclusion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 25

    Jun

NOK

Nokia

$4.87

0.05 (1.04%)

17:49
01/15/18
01/15
17:49
01/15/18
17:49
Hot Stocks
Nokia wins five-year managed services agreement to manage Optus' network »

Nokia and Optus have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSTR

MicroStrategy

$139.75

1.39 (1.00%)

, AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

17:47
01/15/18
01/15
17:47
01/15/18
17:47
Hot Stocks
MicroStrategy announces rollout of MicroStrategy Partner Program »

MicroStrategy (MSTR)…

MSTR

MicroStrategy

$139.75

1.39 (1.00%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

MSFT

Microsoft

$89.60

1.52 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

  • 18

    Mar

DAR

Darling Ingredients

$19.15

0.41 (2.19%)

17:37
01/15/18
01/15
17:37
01/15/18
17:37
Hot Stocks
Darling Ingredients announces new CFO, Chief Administrative Officer »

Darling Ingredients…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AON

Aon plc

$136.55

1.28 (0.95%)

17:34
01/15/18
01/15
17:34
01/15/18
17:34
Hot Stocks
Aon declares quarterly dividend of 36c per share »

Aon announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$20.59

0.39 (1.93%)

17:32
01/15/18
01/15
17:32
01/15/18
17:32
Hot Stocks
KBR assures no disruptions on U.K. defense project »

KBR announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 25

    Jun

TRQ

Turquoise Hill

$3.57

0.06 (1.71%)

17:30
01/15/18
01/15
17:30
01/15/18
17:30
Hot Stocks
Turquoise Hill announces that Oyu Tolgoi received $155M Tax Act »

Turquoise Hill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.